Your browser doesn't support javascript.
loading
Clinical features and outcomes of COVID-19 in patients with solid tumors: Turkish National Registry Data.
Özdemir, Nuriye; Dizdar, Ömer; Yazici, Ozan; Aksoy, Sercan; Dede, Didem Sener; Budakoglu, Burçin; Metan, Gökhan; Alp, Alpaslan; Budakoglu, Isil Irem; Öksüzoglu, Ömür Berna Çakmak; Özet, Ahmet; Kiliçkap, Saadettin; Turhal, Nazim Serdar; Çelik, Ismail; Erman, Mustafa; Ata, Naim; Çelik, Osman; Hayran, Mutlu.
Afiliación
  • Özdemir N; Department of Medical Oncology, Gazi University School of Medicine, Ankara, Turkey.
  • Dizdar Ö; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
  • Yazici O; Department of Medical Oncology, Gazi University School of Medicine, Ankara, Turkey.
  • Aksoy S; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
  • Dede DS; Department of Medical Oncology, Anakar Yildirim Beyazit University School of Medicine, Ankara, Turkey.
  • Budakoglu B; Department of Medical Oncology, Medikalpark Medical Center, Ankara, Turkey.
  • Metan G; Department of Infectious diseases and Clinical Microbiology, Hacettepe University School of Medicine, Ankara, Turkey.
  • Alp A; Department of Clinical Microbiology, Hacettepe University School of Medicine, Ankara, Turkey.
  • Budakoglu II; Department of Medical Education and Informatics, Gazi University School of Medicine, Ankara, Turkey.
  • Öksüzoglu ÖBÇ; Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
  • Özet A; Department of Medical Oncology, Gazi University School of Medicine, Ankara, Turkey.
  • Kiliçkap S; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
  • Turhal NS; Department of Medical Oncology, Istanbul Anadolu Medical Center and President of Turkish Medical Oncology Association, Istanbul, Turkey.
  • Çelik I; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
  • Erman M; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
  • Ata N; Strategy Development Department of the Ministry of Health, Ankara, Turkey.
  • Çelik O; Strategy Development Department of the Ministry of Health, Ankara, Turkey.
  • Hayran M; Department of Preventive Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Int J Cancer ; 148(10): 2407-2415, 2021 May 15.
Article en En | MEDLINE | ID: mdl-33284987
We present demographic, clinical, laboratory characteristics and outcomes of the patients with solid malignancies and novel coronavirus disease (COVID-19) collected from the National COVID-19 Registry of Turkey. A total of 1523 patients with a current or past diagnosis of solid tumors and diagnosed with COVID-19 (confirmed with PCR) between 11 March and 20 May 2020 were included. The primary outcome was 30-day mortality. Median age was 61 (range: 18-94), and 752 (49%) were male. The most common types of cancers were breast (19.8%), prostate (10.9%) and colorectal cancer (10.8%). 65% of the patients had at least one comorbidity. At least one COVID-19-directed therapy was given in 73% of the patients.. Hospitalization rate of the patients was 56.6% and intensive care unit admission rate was 11.4%. Seventy-seven (5.1%) patients died within 30 days of diagnosis. The first multivariate model which included only the demographic and clinical characteristics showed older age, male gender and presence of diabetes and receipt of cytotoxic therapy to be associated with increased 30-day mortality, while breast and prostate cancer diagnoses were associated with lower 30-day mortality. In the second set, we further included laboratory parameters. The presence of leukocytosis (OR 6.7, 95% CI 3.3-13.7, P < .001), lymphocytopenia (OR 3,1, 95% CI 1,6-6,1, P = .001) and thrombocytopenia (OR 3,4 95% CI 1,5-8,1, P = .005) were found to be associated with increased 30-day mortality. Relatively lower mortality compared to Western countries and China mainly results from differences in baseline risk factors but may also implicate the importance of intensive supportive care.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Int J Cancer Año: 2021 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Int J Cancer Año: 2021 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Estados Unidos